Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT05940480
Active, not recruiting Not applicable

TCM Daoyin Therapy in Individuals At-risk for COPD

NCT05940480 · tracked via the Priya Life Science China tracker
Sponsor
Shanghai University of Traditional Chinese Medicine
Phase
Not applicable
Started
2023-01-03
Last updated
2026-04-29

Condition(s) studied

Chronic Obstructive Pulmonary DiseaseLung Diseases, Obstructive

Investigational drug(s) / intervention(s)

TCM DaoyinHealth education

TCM Daoyin: The TCM Daoyin training program consisted of two 90-min training classes and at least five 30-min at-home practice sessions per week for 16-weeks. All sessions included 10 min of warmup and 10 min of cooldown.

Health education: Health education is provided by doctor and nurse, including work, rest, diet and other basic programs.

Study summary

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable disease. The aim of prospective randomized study is to evaluate the effects of TCM Daoyin training on Individuals at-risk for COPD.

Eligibility

Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Subject at-risk for COPD (Chronic obstructive pulmonary disease screening questionnaire (COPD-SQ) score≥16; and pre-bronchodilator FEV1/FVC ≥ 0.70, or pre-bronchodilator FEV1/FVC\<0.70 but post-bronchodilator FEV1/FVC ≥ 0.70). * Aged 40 to 75, male or female. * Subject has a clear mind and the ability to lead an independent life. * Subject agrees to perform a blood-test. * Subject agrees to participate in this study and sign to the informed consent. Exclusion Criteria: * Subject with acute exacerbation of COPD. * Subject with respiratory infectious disease (e.g., tuberculosis, influenza, etc.) within 1 month. * Subject with serious current unstable physical illness and mental illness. * Subject with definite clinical diagnosis of Alzheimer's disease, or severe cognitive impairment. * Subject is pregnant or lactating women.

Primary outcome measure(s)

  • Lung function — Change from Baseline lung function at 16 weeks
    Participants' lung function (FVC、FVC%、FEV1、FEV1%、FEV1/FVC) will be tested to identify air flow condition in both group.

Trial sites (2)

FacilityCityRegionStatus
Shanghai Qigong Research Institute Shanghai Shanghai Municipality
Changzheng Community Health Service Center of Putuo District, Shanghai Shanghai Shanghai Municipality

More Shanghai University of Traditional Chinese Medicine trials in China

TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms Recruiting
Multicenter Cohort Study on Osteoporosis Recruiting
The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma Recruiting
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors Recruiting
EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery Starting soon

Other trials for the same condition

A Study to Evaluate the Efficacy and Safety of RSS0343 Tablets in Patients With Chronic Obstructive Pulmonary Disease Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Recruiting
The Phase Ib Clinical Trial of the XH-S004 Tablet in Patients With Chronic Obstructive Pulmonary Disease (COPD) to Evaluate Its Safety, Tolerability, Pharmacokinetic Characteristics and Pharmacodynamic Characteristics After Multiple Administrations Active, not recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. Recruiting
This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05940480 on ClinicalTrials.gov ↗ ← All trials in China